Published in Springerplus on April 26, 2016
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res (2016) 0.76
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res (2016) 0.76
Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report. Transl Lung Cancer Res (2016) 0.75
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci (2017) 0.75
Liquid Biopsy in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2016) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Tumour heterogeneity in the clinic. Nature (2013) 3.92
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med (2011) 2.19
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer (2015) 1.78
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol (2004) 1.57
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J (2015) 1.56
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res (2015) 1.45
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clin Cancer Res (2015) 1.34
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res (2013) 1.10
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer (2015) 0.92
Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J (Engl) (2004) 0.86